Abstract
The progress of medicine in the past relied on the development of pharmacological agents, most of which were empirically extracted from plants. A second important phase of medical progress was the discovery of vaccination, which not only led to an understanding of the complexity of the immune response, but also to a systematic method of treating a variety of transmissible diseases. The third important step in the development of medicine was the transplantation of organs where, again, the main progress came from the understanding and control of the immune response. The usefulness of organ transplantation is, however, currently limited by the availability of organs. A solution to this problem may reside in the transplantation of cells proliferated in culture, a possibility that has triggered a burst of research activity. Cell transplantation, that is the use of myoblasts, could potentially be used to treat several dystrophies (Law, Goodwin, and Wang 1988; Morgan, Watt, Sloper, and Partridge 1988; Partridge, Morgan, Coulton, Hoffman, and Kunkel 1989). Gene therapy treatment of hereditary diseases as well as many acquired diseases and conditions will be another important development in the medicine of the next century. Both of the new solutions for the future of medicine are, however, faced with a very old problem: our limited understanding and even more limited control of the immune response.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Boulanger, A., Asselin, I., Roy, R., and Tremblay, J.P. 1997. Role of nonmajor histocompatibility complex antigens in the rejection of transplanted myoblasts. Transplantation 63:893–9.
Chahine, A.A., Yu, M., McKernan, M.M., Stoeckert, C., and Lau, H.T. 1995. Immunomodulation of pancreatic islet allografts in mice with CTLA-4Ig secreting muscle cells. Transplantation 59:1313–18.
Cosimi, A.B. 1995. Future of monoclonal antibodies in solid organ transplantation. Dig Dis Sci 40:65–72.
Day, C.S., Kasemkijwattana, C., Ménétrey, J., Floyd, S.S., Booth, D.K., Moreland, M.S., Fu, F.H., and Huard, J. 1997. Myoblast mediated gene transfer to the joint. J Orthop Res 15:894–903.
Deschênes, I., Chahine, M., Tremblay, J., Paulin, D., and Puymirat, J. 1997. Increase in the proliferative capacity of human myoblasts by using the T antigen under the vimentin promoter control. Muscle Nerve 20:437–45.
Gahery-Segard, H., Farace, F., Godfrin, D., Gaston, J., Lengagne, R., Tursz, T., Boulanger, P., and Guillet, J.G. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and antipenton base antibodies have a synergistic effect on neutralizing activity. J Virol 72(3):2388–97.
Gahery-Segard, H., Juillard, V., Gaston, J., Lengagne, R., Pavirani, A., Boulanger, P., and Guillet, J.G. 1997. Humoral immune response to the capsid components of recombinant adenoviruses: routes of immunization modulate virus induced Ig subclass sifts. Eur J Immunol 27(3):653–9.
Guérette, B., Asselin, I., Vilquin, J.T., Roy, R., and Tremblay, J.P. 1994. Lymphocyte infiltration following allo and xeno myoblast transplantation in mice. Transp Proc 26:4061–2.
Guérette, B., Gingras, M., Wood, K., Roy, R., and Tremblay, J.P. 1996. Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. Transplantation 62(7):962–7.
Hauser, M.A., Amalfitano, A., Kumar-Singh, R., Hauschka, S.D., and Chamberlain, J.S. 1997. Improved adenoviral vectors for gene therapy of Duchenne muscular dystrophy. Neuromusc Disord 7:277–83.
Huard, J., Bouchard, J.P., Roy, R., Malouin, F., Dansereau, G., Labrecque, C., Albert, N., Richards, C.L., Lemieux, B., and Tremblay, J.P. 1992. Human myoblast transplantation: preliminary results of 4 cases. Muscle Nerve 15:550–60.
Huard, J., Verreault, S., Roy, R., Tremblay, M., and Tremblay, J.P. 1994. High efficiency of muscle regeneration after human myoblast clone transplantation in SCID mice. J Clin Invest 93:586–99.
Karpati, G., Pouliot, Y., Zubrzycka-Gaan, E., Carpenter, S., Ray, P.N., Worton, R.G., and Holl, P. 1989. Dystrophin is expressed in mdx skeletal myscle fibers after normal myoblast inmplantation. Am J Path 135:27–32.
Kay, M.A., Holterman, Z.X., Meuse, L., Gown, A., Ochs, H.D., Linsley, P.S., and Wilson, C.B. 1995. Long term hepatic adenovirus mediated gene expression in mice following CTLA4-Ig administration. Nat Genet 11:191–7.
Kinoshita, I., Vilquin, J.T., Gravel, C., Roy, R., and Tremblay, J.P. 1995. Myoblast allotransplantation in primates. Muscle Nerve 18:1217–18.
Kinoshita, I., Vilquin, J.T, Guérette, B., Asselin, I., Roy, R., and Tremblay, J.P. 1994. Very efficient myoblast allotransplantation in mice under FK506 immunosuppression. Muscle Nerve 17:1407–15.
Kochanek, S., Clemens, Mitani, K., Chen, H.H., Chan, S., and Caskey, C.T 1996. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full length dystrophin and B-galactosidase. Proc Natl Acad Sci USA 93(12):5731–6.
Law, P.K., Goodwin, T.G., and Wang, M. 1988. Normal myoblast injections provide genetic treatment for murine dystrophy. Muscle Nerve 11(6):525–33.
MacDonald, T.T 1994. Oral tolerance: eating your way towards immunosuppression. Curr Biol 4:178–81.
Lehrman S. 1999. Virus treatment questioned after gene therapy. Death Nature 401:517–18.
Morgan, J.E., Watt, D.J., Sloper, J.C., and Partridge, T.A. 1988. Partial correction of an inherited biochemical defect of skeletal muscle by grafts of normal muscle precursor cells. J Neurol Sci 86:137–47.
Naji, A. 1996. Induction of tolerance by intrathymic inoculation of alloantigen. Curr Opin Immunol 8:704–9.
Oluwole, S.F., Jin, M.X., Chowdhury, N.C., Engelstad, K., Ohajekwe, O.A., and James, T. 1995. Induction of peripheral tolerance by intrathymic inoculation of soluble alloantigens: evidence for the role of host antigen presenting cells and suppressor cell mechanism. Cell Immunol 162:33–41.
Partridge, T.A., Morgan, J.E., Coulton, G.R., Hoffman, E.P., and Kunkel, L.M. 1989. Conversion of mdx myofibres from dystrophin negative to positive by injection of normal myoblasts. Nature 337:176–9.
Rossini, A.A., Greiner, D.L., and Mardes, J.P 1999. Induction of immunologic tolerance for transplantation. Physiol Rev 79(1):99–141.
Skuk, D., Roy, B., Goulet, M., and Tremblay, J.P. 1999. Successful myoblast transplantation in primates depends on appropriate cell delivery and induction of regeneration in host muscle. Exp Neurol 155(1):22–30.
Tremblay, J.P. and Guérette, B. 1997. Myoblast transplantation: identification of the problems and some solutions. Basic Appl Myol 7:221–30.
Tremblay, J.P., Malouin, F., Roy, R., Huard, J., Bouchard, J.P., Satoh, A., and Richard, C.L. 1993. Results of triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. Cell Trans 2:99–112.
van Schilfgaarde R. and de Vos P. 1999. Factors influencing the properties and pre-formance of microcapsules for immunoprotection of pancreatic islets. J Mol Med 77(1):199–205.
Vilquin, J.T, Guérette, B., Kinoshita, I., Roy, B., Goulet, M., Gravel, C., Roy, R., and Tremblay, J.P 1995. FK506 immunosuppression to control the immune reactions triggered by first generation adenovirus-mediated gene transfer. Hum Gene Ther 6:1391–401.
Vilquin, J.T, Wagner, E., Kinoshita, I., Roy, R., and Tremblay, J.P 1995. Successful histocompatible myoblast transplantation in dystrophin deficient mdx mouse despite the production of antibodies against dystrophin. J Cell Biol 131:975–88.
Weiner, H.L., Friedman, A., Miller, A., Khoury, S.J., Al-Sabbagh, A., Santos, L., Sayegh, M., Nussenblatt, R.B., Trentham, D.E., and Hafler, D.A. 1994. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 12:809–37.
Yang, Y., Kaecker, S.E., Su, Q., and Wilson, J.M. 1996. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle. Hum Mol Genet 5(11):1703–12.
Yang, Y., Nunes, F.A., Berencsi, K., Furth, E.E., Gönczöl, E., and Wilson, J.M. 1994. Cellular immunity to viral antigens limits E1 deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 91:4407–11.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Birkhäuser Boston
About this chapter
Cite this chapter
Tremblay, J.P. (2000). Immune Reaction Following Cell and Gene Therapy. In: Huard, J., Fu, F.H. (eds) Gene Therapy and Tissue Engineering in Orthopaedic and Sports Medicine. Methods in Bioengineering. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-2126-5_13
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2126-5_13
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-7424-7
Online ISBN: 978-1-4612-2126-5
eBook Packages: Springer Book Archive